Other languages Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
8.2 ^USD	0.00%		-4.76%	+4.06%

Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI
Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics Shares Rise After BTIG Upgrade	Mar. 27
Outlook Therapeutics Reports Secondary Share Offering	Mar. 25
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 22
Sector Update: Health Care Stocks Ease Friday Afternoon	Mar. 22
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	Mar. 22
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 22
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -	Mar. 19
Outlook Therapeutics lève 60 millions de dollars pour l'approbation de son bevacizumab	Mar. 19
Outlook Therapeutics Shares Climb Following Upgrade by Chardan	Feb. 15
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14
Outlook Therapeutics Doses First Patient in Eye Disease Study	Jan. 31
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	Jan. 31
Sector Update: Health Care Stocks Decline Late Afternoon	Jan. 23
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Jan. 23
Outlook Therapeutics Says FDA Clarifies Steps for ONS-5010 Study, Enters Securities Purchase Deals	Jan. 23
Outlook Therapeutics :bondit après plusieurs bonnes nouvelles pour son produit ONS-5010	Jan. 23
Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT	Jan. 23
Outlook Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 22
Outlook Therapeutics :réduit ses pertes en 2023	Dec. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Other languages

Filters